We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
Read MoreHide Full Article
Key Takeaways
Spyre Therapeutics shares surged 73% after SPY001 met the primary endpoint in the UC mid-stage study.
SPY001 showed 40% remission and 51% endoscopic improvement with a favorable safety profile.
Spyre highlighted SPY001 may outperform rivals, with extended dosing vs Takeda's Entyvio.
Shares of Spyre Therapeutics (SYRE - Free Report) have surged 73% over the past month after the company reported encouraging data from a mid-stage study evaluating its investigational anti-α4β7 drug, SPY001, in patients with moderate-to-severe ulcerative colitis (UC).
The drug met the primary endpoint, delivering a statistically significant 9.2-point reduction in the Robarts Histopathology Index (RHI) — a key measure of tissue-level inflammation in UC — after 12 weeks of treatment. Data from the study showed that treatment with the drug achieved a 40% clinical remission rate and a 51% endoscopic improvement rate.
In addition to strong efficacy, SPY001 demonstrated a favorable safety profile that was consistent with the α4β7 class. Spyre reported that six participants experienced treatment-emergent adverse events, including one serious adverse event that was not considered drug-related. The most common side-effect was back pain.
These results come from Part A of the SKYLINE study, which is evaluating Spyre’s anti-TL1A antibody SPY002 and anti-IL-23 antibody SPY003. While Part A is an open-label phase assessing each drug individually, Part B will be a randomized, placebo-controlled stage evaluating different doses and combinations of these therapies.
Initial data from the SPY002 and SPY003 cohorts in Part A of the SKYLINE study are expected in mid-2026 and the third quarter of 2026, respectively.
What Makes SYRE’s Results So Special?
SPY001 targets the same α4β7 integrin pathway as Takeda Pharmaceutical’s (TAK - Free Report) blockbuster drug Entyvio (vedolizumab), a well-established therapy in UC. Spyre has designed its drug with an extended half-life and optimized dosing, which may enable higher drug exposure and potentially less frequent maintenance dosing than the TAK drug, improving both efficacy and patient convenience.
This differentiated profile likely contributed to the recent surge in SYRE shares. Year to date, the stock has rallied 123% compared with the industry’s 1% growth.
Image Source: Zacks Investment Research
The company highlighted that SPY001’s efficacy compares favorably not only within the α4β7 class but against therapies across other mechanisms. In a conference call, management claimed that the efficacy data reported in the SKYLINE study were higher than those reported for either combination component in Johnson & Johnson’s (JNJ - Free Report) mid-stage VEGA study.
This J&J study evaluated the IL-23 inhibitor Tremfya (guselkumab) and anti-TNF therapy Simponi (golimumab) as induction therapy in UC patients, aiming to improve outcomes by targeting multiple inflammatory pathways simultaneously.
View the Zacks #1 Rank List
Image: Bigstock
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
Key Takeaways
Shares of Spyre Therapeutics (SYRE - Free Report) have surged 73% over the past month after the company reported encouraging data from a mid-stage study evaluating its investigational anti-α4β7 drug, SPY001, in patients with moderate-to-severe ulcerative colitis (UC).
The drug met the primary endpoint, delivering a statistically significant 9.2-point reduction in the Robarts Histopathology Index (RHI) — a key measure of tissue-level inflammation in UC — after 12 weeks of treatment. Data from the study showed that treatment with the drug achieved a 40% clinical remission rate and a 51% endoscopic improvement rate.
In addition to strong efficacy, SPY001 demonstrated a favorable safety profile that was consistent with the α4β7 class. Spyre reported that six participants experienced treatment-emergent adverse events, including one serious adverse event that was not considered drug-related. The most common side-effect was back pain.
These results come from Part A of the SKYLINE study, which is evaluating Spyre’s anti-TL1A antibody SPY002 and anti-IL-23 antibody SPY003. While Part A is an open-label phase assessing each drug individually, Part B will be a randomized, placebo-controlled stage evaluating different doses and combinations of these therapies.
Initial data from the SPY002 and SPY003 cohorts in Part A of the SKYLINE study are expected in mid-2026 and the third quarter of 2026, respectively.
What Makes SYRE’s Results So Special?
SPY001 targets the same α4β7 integrin pathway as Takeda Pharmaceutical’s (TAK - Free Report) blockbuster drug Entyvio (vedolizumab), a well-established therapy in UC. Spyre has designed its drug with an extended half-life and optimized dosing, which may enable higher drug exposure and potentially less frequent maintenance dosing than the TAK drug, improving both efficacy and patient convenience.
This differentiated profile likely contributed to the recent surge in SYRE shares. Year to date, the stock has rallied 123% compared with the industry’s 1% growth.
Image Source: Zacks Investment Research
The company highlighted that SPY001’s efficacy compares favorably not only within the α4β7 class but against therapies across other mechanisms. In a conference call, management claimed that the efficacy data reported in the SKYLINE study were higher than those reported for either combination component in Johnson & Johnson’s (JNJ - Free Report) mid-stage VEGA study.
This J&J study evaluated the IL-23 inhibitor Tremfya (guselkumab) and anti-TNF therapy Simponi (golimumab) as induction therapy in UC patients, aiming to improve outcomes by targeting multiple inflammatory pathways simultaneously.
Spyre Therapeutics, Inc. Price
Spyre Therapeutics, Inc. price | Spyre Therapeutics, Inc. Quote
SYRE’s Zacks Rank
Spyre currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.